The ongoing struggle to enable access to sofosbuvir globally at affordable prices continues with several new developments.
On May 20th, additional patent challenges against Gilead's sofosbuvir in Argentina, Brazil, China, Russia and Ukraine were filed by community organisations.1
The challenges were filed by Initiative of Medicines, Access and Knowledge (I-MAK), Grupo de Trabalho sobre Propriedade Intelectual (Brazil), All-Ukrainian Network of People Living with HIV/AIDS, Treatment Preparedness Coalition (Russia) and Fundación Grupo Efecto Positivo (Argentina).
On the same day, demonstrations and protests were announced in Thailand and Tunisia by AIDS Access Foundation (Thailand), The Tunisian Association of Fight Against STDs and AIDS and International Treatment Preparedness Coalition (Middle East North Africa).
In January, the Indian Patent Controller rejected one of Gilead's key patent applications for sofosbuvir.2
Other activists in Asia are tracking the approval status and price of eleven current generic versions of sofosbuvir being manufactured in India under license form Gilead. This is updated when new information becomes available.3
A month later, the Paris-based Médecins du Monde (MDM) group challenged the patent in the EU, alleging that the active ingredient in Sovaldi (sofosbuvir) "is the result of work by many public and private researchers [and] is not sufficiently innovative to warrant a patent."4
In England, delays and restrictions to access -- especially for anyone who does not have cirrhosis -- were highlights by the Hepatitis C Trust.5
"Sofosbuvir will be available from 1 August 2015 -- with peginterferon and ribavirin for genotype 1 and for those with cirrhosis who have genotypes 3, 4, 5 or 6 (or who have previously tried treatment for those with genotype 3) and in very limited cases without interferon. NICE's assessments of sofosbuvir in combination with ledipasvir (Harvoni), daclatasvir in combination with one or more other drugs and ombitasvir with paritaprevir and dasabuvir have all been paused while NICE considers a request from NHS England to limit availability because of the cost."
The Hepatitis C Trust is urging patients to write to their MPs and include a template letter online.6
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|